Osteopontin (2-O-Me OPN-R3) Aptamer Details

ID# 7737

Back to Search Results

Structure

Chemistry

Chimeric

Target

Human Osteopontin

Sequence (3-char table code)

G A C U/T

5'-mCprGprGpmCpmCprApmCprAprGprAprApmUprGprAprAprAprAprApmCpmCpmUpmCprApmUpmCprGprApmUprGpmUpmUprGpmCprApmUprAprGpmUpmUprGp-3'

Molecular Weight: 13079.35

Extinction Coefficient: 402900

Binding Conditions / Buffer

Binding Buffer: PBS (137 nM NaCl, 27 nM KCl, 100 nM Na2HPO4, 2 nM K2HPO4, pH 7.4)

Binding Temp: 37°C

Refolding Protocol

If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference

Z Mi et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy 17(2009): 153-161 Li J, Yousefi K, Ding W, Singh J, Shehadeh LA. Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure. Cardiovasc Res. 2017 May 1;113(6):633-643. doi: 10.1093/cvr/cvx016. PMID: 28453726; PMCID: PMC7526752.

Request a Quote Have your aptamer oligo synthesized by Aptagen.